OncLive: Dr. Mesa on the rationale for the earlier use of ruxolitinib in myelofibrosis

In this video, Ruben Mesa, MD, executive director of the Mays Cancer, discusses the rationale for the earlier use of ruxolitinib (Jakafi) in myelofibrosis.

Watch the interview.